BRAINSTORM CELL THERAPEUTICS INC. Number of Reportable Segments
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:NumberOfReportableSegments · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment.
- BRAINSTORM CELL THERAPEUTICS INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- BRAINSTORM CELL THERAPEUTICS INC. number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-31 | ||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |